Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdCLD-CoV19-1 OMI Booster for COVID-19 Prevention
NCT05993325Phase 3Active, not recruiting
- Sponsor
- Cellid Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of AdCLD-CoV19-1 OMI in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cellid Co., Ltd. Primary endpoints: Ratio of GMT of SARS-CoV-2 B.1.1.529 neutralizing antibody at 28 days and Difference in seroresponse rate (SRR) of SARS-CoV-2 B.1.1.529 neutralizing antibody at 28 days. Started Nov 2023; status: active, not recruiting.
02
Drugs
AdCLD-CoV19-1 OMI
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05993325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993325.